Total Holdings
45
As of Oct 4, 2026
KraneShares MSCI All China Health Care Index ETF
KURENYSEARCAKraneSharesEquity
$17.65Today:- (-)1Y −8.91%
As of Oct 16, 2026 close
- Assets (AUM)
- $114.29M
- Expense ratio
- 0.65%
- Dividend yield
- 3.99%
- Holdings
- 45
- 52-week range
- $14.38$19.93
- Volume (live)
- -
- Avg. volume (3M)
- 90.87K
KURE ETF Holdings: KraneShares MSCI All China Health Care Index ETF
Every listed position with its portfolio weight, plus sector breakdown and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Top 10 Holdings
59.7%
Share of fund assets
Assets (AUM)
$114.29M
Total fund assets
Expense Ratio
0.65%
Annual management fee
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
All 47 KURE Holdings by Portfolio Weight
Holdings as of Oct 4, 2026. Ticker, name, asset type and portfolio weight for each position.
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 | HKG:1801 | Innovent Biologics Inc | Stock | 9.09% |
| 2 | HKG:6160 | BeOne Medicines AG | Stock | 8.83% |
| 3 | HKG:2269 | WuXi Biologics (Cayman) Inc. | Stock | 8.06% |
| 4 | SHA:603259 | WuXi AppTec Co., Ltd. | Stock | 5.79% |
| 5 | SHG:603259 | WuXi AppTec Co Ltd | Stock | 5.62% |
| 6 | SHE:300760 | Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A | Stock | 4.78% |
| 7 | HKG:9926 | Akeso, Inc. | Stock | 4.68% |
| 8 | SHG:600276 | Jiangsu Hengrui Medicine Co Ltd | Stock | 4.48% |
| 9 | SHA:600276 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Stock | 4.45% |
| 10 | HKG:1177 | Sino Biopharmaceutical Limited | Stock | 3.97% |
| 11 | HKG:1093 | CSPC Pharmaceutical Group Limited | Stock | 3.78% |
| 12 | HKG:1548 | Genscript Biotech Corporation | Stock | 3.61% |
| 13 | HKG:2359 | WuXi AppTec Co., Ltd. | Stock | 3.37% |
| 14 | HKG:3692 | Hansoh Pharmaceutical Group Co Ltd | Stock | 3.12% |
| 15 | SHE:000538 | Yunnan Baiyao Group Co Ltd | Stock | 2.21% |
| 16 | HKG:1530 | 3SBio Inc | Stock | 2.17% |
| 17 | SHG:688271 | Shanghai United Imaging Healthcare Co. Ltd. A | Stock | 2.15% |
| 18 | SHA:688271 | Shanghai United Imaging Healthcare Co., Ltd. | Stock | 2.07% |
| 19 | HKG:6990 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Stock | 2.01% |
| 20 | SHE:300015 | Aier Eye Hospital Group | Stock | 1.89% |
| 21 | SHG:600436 | Zhangzhou Pientzehuang Pharmaceutical Co Ltd | Stock | 1.81% |
| 22 | SHA:600436 | Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. | Stock | 1.67% |
| 23 | SHG:688506 | Sichuan Biokin Pharmaceutical Co. Ltd. A | Stock | 1.60% |
| 24 | SHE:002422 | Sichuan Kelun Pharmaceutical Co Ltd | Stock | 1.58% |
| 25 | SHE:300759 | Pharmaron Beijing Co., Ltd. | Stock | 1.56% |
| 26 | HKG:2228 | XtalPi Holdings Limited | Stock | 1.53% |
| 27 | SHA:688506 | Sichuan Biokin Pharmaceutical Co.,Ltd. | Stock | 1.52% |
| 28 | HKG:1099 | Sinopharm Group Co. Ltd | Stock | 1.49% |
| 29 | SHE:002821 | Asymchem Laboratories (Tianjin) Co., Ltd. | Stock | 1.47% |
| 30 | SHE:002653 | Xizang Haisco Pharmaceutical Group Co Ltd | Stock | 1.42% |
| 31 | HKG:2268 | WuXi XDC Cayman Inc | Stock | 1.20% |
| 32 | SHG:688578 | Shanghai Allist Pharmaceuticals Co. Ltd. A | Stock | 1.18% |
| 33 | SHG:600196 | Shanghai Fosun Pharmaceutical Group Co Ltd | Stock | 1.17% |
| 34 | SHE:000963 | Huadong Medicine Co Ltd | Stock | 1.17% |
| 35 | SHG:601607 | Shanghai Pharmaceuticals Holding Co Ltd | Stock | 1.13% |
| 36 | SHG:688331 | RemeGen Co. Ltd. A | Stock | 1.06% |
| 37 | HKG:0999 | Xiaocaiyuan Intl Hldg Ltd | Stock | 1.02% |
| 38 | SHE:000999 | China Resources Sanjiu Medical & Pharmaceutical Co Ltd | Stock | 1.01% |
| 39 | SHE:300832 | Shenzhen New Industries Biomedical | Stock | 0.95% |
| 40 | SHE:300765 | CSPC Innovation Pharmaceutical Co Ltd Class A | Stock | 0.90% |
| 41 | SHE:002294 | Shenzhen Salubris Pharmaceuticals Co Ltd | Stock | 0.84% |
| 42 |  | Legend Biotech Corporation | Stock | 0.84% |
| 43 | SHG:688617 | APT Medical Inc | Stock | 0.83% |
| 44 | SHG:600085 | Beijing Tongrentang Co Ltd | Stock | 0.81% |
| 45 | SHE:002252 | Shanghai RAAS Blood Products Co Ltd Class A | Stock | 0.81% |
| 46 | SHE:300896 | Imeik Technology Development Co | Stock | 0.69% |
| 47 | SHE:300347 | Hangzhou Tigermed Consulting | Stock | 0.48% |
Source: Fund holdings disclosures. Data as of Oct 4, 2026. Data sources and methodology
Frequently Asked Questions About KraneShares MSCI All China Health Care Index ETF Holdings
What are the top holdings in KURE?
As of Oct 4, 2026, KraneShares MSCI All China Health Care Index ETF (KURE) holds 45 securities. The largest are Innovent Biologics Inc (9.09%), BeOne Medicines AG (8.83%), WuXi Biologics (Cayman) Inc. (8.06%). The holdings table lists each position by portfolio weight with its ticker, name and asset type.
How concentrated is KURE's portfolio?
As of Oct 4, 2026, the 10 largest positions make up 59.7% of KURE's assets. A concentrated portfolio has fewer large positions with higher individual weights, while a diversified portfolio distributes holdings more evenly.
What is KURE's sector allocation?
The Sector Allocation chart shows how KURE distributes investments across different industries like Technology, Healthcare, Financials, and more. This sector exposure helps understand the fund's industry diversification strategy.
What countries does KURE invest in?
KURE's geographic exposure is shown in the Countries tab under Portfolio Allocations. This reveals the fund's international diversification and exposure to different regions and global markets.
How diversified is KURE ETF?
KURE's diversification can be assessed by reviewing its 45 holdings (as of Oct 4, 2026), sector allocation, and geographic exposure. A well-diversified ETF spreads investments across multiple securities, sectors, and regions to reduce concentration risk.